INVEST IN STRANDSMART TODAY!
Next generation, cell-based liquid biopsy
$35,354.71 Raised
Reasons to Invest
- Utilizing liquid biopsies for precision medicine is already a $4B market and is estimated to grow to $10B by the end of the decade.
- Current technologies serving the market rely only on the DNA from tumors to drive their test results and drug prediction. StrandSmart leverages the tumor cell itself, where we can analyze and characterize the DNA, RNA, and proteins to provide a 360 view of the biologic drivers of the tumor, enabling us to develop the most accurate and comprehensive test on the market.
- Founded in 2017, we already have lab operations in Columbus, Ohio, and are backed by a management team with 8+ venture exits. Most importantly, three of the cofounders launched the first and only FDA-approved liquid biopsy CTC test.
*(source)
Overview
The future of liquid biopsy
Cancer sometimes happens so fast, it often leaves people feeling helpless in their search for solutions. That’s why at StrandSmart - instead of chasing cancer, we aim to get ahead of it, stopping it in its tracks before it makes its next move. The Company is currently pre-revenue and in the development stage.
This is now possible with technologies such as single-cell sequencing, which allows us to read the signals expressed by millions of cells at once from a given blood sample.
As a next-generation cell-based liquid biopsy company, we focus on profiling live tumor cells to guide therapy selection, patient monitoring, and therapeutic discovery & development. This is all to better help cancer patients on their road to recovery.
The Problem & Our solution
Oncologists are limited in determining how cancer patients will respond to certain treatments. Our live cell characterization provides additional information, which can enable improved decision making.
90% of cancer deaths are due to treatment failure, as cancer is a moving target that changes and evolves (source).
Liquid biopsy tests on the market today can only identify known cancer mutations - which is only about 10% of all cancers (source).
StrandSmart alerts physicians of these mutations so they can respond with alternative interventions - that we believe can lead to better outcomes. StrandSmart can extract the same mutation data as other, and in addition augment the information by adding transcriptomic, and proteomic data. The 360 degree view of cancer will predict whether a patient will respond to a drug for a much broader patient population (source). By keeping cells alive after extracting them from a blood sample, we equip oncologists and drug developers with the information needed to get the best possible outcomes for patients.
In addition, by keeping cells alive after extracting them from a blood sample, we equip oncologists and drug developers with the information needed to get the best possible outcomes for patients.
We generate revenue by selling lab tests to biotech and pharmaceutical companies that are developing cancer therapies (Research Market) and oncologists who are treating cancer patients (Cancer diagnostics).
THE MARKET & OUR TRACTION
The liquid biopsy market is a nascent industry that is experiencing rapid growth in revenue
That’s because, in the US alone, there are …
Sources: Cancer.org, Cancer.org, Cancer.org , Cancer.org, Verzenio, Komen, Zero Cancer
We are initially targeting the post-diagnosis oncology market. Our first tests are for metastatic lung, breast, and prostate cancer patients.
So far, these markets have had to rely on a limited amount of information from the sequencing of DNA for mutations only (source). With that, we believe the timing for StrandSmart is critical. Not only have we overcome the limitations of predecessor technologies for capturing Circulating-Tumor-Cells (CTCs), but the advent of single-cell sequencing technologies enables us to fully exploit them and unload the cargo of information they carry to improve outcomes.
Here’s a look at our progress to date:
WHY INVEST
Our vision is a world where cancer is no longer a terminal disease
We think cancer should be managed as a chronic disease that doesn’t interfere with the quality of life or life expectancy. With that, we want to make personalized cancer treatment accessible to everyone, and at the same time, accelerate the ability of the drug development community to develop new treatments to address all cancer diseases.
Over the next few years, we aim to…
The advent of genomics and sequencing technology over the last 10 years has already changed how we view and treat cancer with an understanding of DNA and cancer mutations.
StrandSmart sees itself as the driver of the next wave of this progress - all by putting comprehensive data of an individual patient’s cancer in the hands of the oncologists and drug developers battling the disease on the front lines. Invest in our mission today!
ABOUT
HEADQUARTERS
501 W. BROADWAY SUITE 800
SAN DIEGO, CA 92101
WEBSITE
View Site
StrandSmart is developing a next-generation liquid biopsy (blood) test to enable precision medicine, or the ability to identify the biological driver of a tumor, allowing us to better match the right drug to the individual patient. We are pre-revenue, and are in development, working with academics and pharma to further validate our technology so that we can launch our blood tests to oncologists, giving them the tools to help improve and extend patients’ lives.
TEAM
Adrianna Davies
Founder & CEO
John Park MD
Chief Scientific Officer
Rex Yung MD
Chief Medical Advsior
College in Cambridge, Massachusetts. He followed up with matriculation at the University of
California in Los Angeles (UCLA), School of Medicine, and after a year in cardiovascular
research funded by an American Heart Association medical student research fellowship,
returned to clinical training in internal medicine at UCLA. His fellowship training in clinical
Pulmonary and Critical Care medicine was completed at the University of California in San
Francisco’s (UCSF) campuses and research at the UCSF Cardiovascular Research Institute.
Dr. Yung’s first academic appointment was at the University of Southern California where as an
assistant professor of pulmonary & critical care medicine, he was engaged in a broad range of
clinical activities; attending on the consult service, Surgical and Neuro intensive care units,
outpatient subspecialty clinic in Cystic Fibrosis and obstructive lung diseases. His own interest
in lung cancer, advanced diagnostic and interventional bronchoscopy led him to focus on
thoracic oncology. He was recruited to Johns Hopkins University where he served as the
Director of Pulmonary Oncology on the pulmonary service and for some years as the Director of
Bronchoscopy as well.
Nationally and internationally he has been recognized as an expert in the field of
advanced bronchoscopy and thoracic oncology, and have served in leadership positions with
the American College of Chest Physicians, Asia Pacific Society of Respirology, executive
boards of the American Association of Bronchoscopy and International pulmonology, the World
Association of Bronchology and Interventional Pulmonology amongst other national and
international subspecialty medical societies. He has conducted sponsored basic pre-clinical
and clinical research, and have served on various advisory boards of established medical
industry leaders in his field of specialty, such as Olympus, Fujinon, Karl Storz, Boston Scientific,
Philips Imaging, General Electric Imaging. He has also been on the early advisory boards of
medical technology start-ups that have successfully exited, such as PneumRx (British
Technology Group), Asthmatx (Boston Scientific). He was recruited to be the Chief Scientific
Office and subsequently the Chief Medical Officer of Prolung / IONIQ Sciences Inc., working on
biomarkers and Clinical Decision Support in lung cancer early detection. Most recently he has
been appointed the chief medical advisor to Strandsmart Inc, a leader in the field of cancer
liquid biopsies, with novel pathfinder technology to combine high yield Circulating Tumor Cell
(CTC) capture with downstream harvesting for tumor cell expression profiling in advancing non-
invasive cancer diagnosis and directing personalized therapy.
Dr. Yung remains committed to patient care and continues to see and care for patients in
the ambulatory and in-patient clinical settings. From his personal international background of
having been born and raised in East Asia, extensive collaboration with physician scientists
across North America, Europe and East Asia, he has a deep appreciation of the value of
engaging in multidisciplinary and public-private partnerships to advance the medical sciences
and effective delivery of efficacious therapies to the bedside.
Mark Connelly PhD
Chief Technology Officer
After 14 years with DuPont and Johnson & Johnson, he was named as Vice President, Reagent Development for Immunicon Corporation and Veridex LLC; where he led the development and commercialization of the CellSearch System. He continued as Scientific Director and Site Directorfor Janssen Diagnostics and became the Chief Industrial Operation and Research andDevelopment Officer, US for Menarini Silicon Biosystems. Over the last 32 years, Dr. Connelly has led the development and commercialization of numerous IVD and RUO products and services in the fields of Clinical Chemistry, Retrovirology, Flow Cytometry, Blood Banking, Autoimmunity, Cancer Diagnostics, and Pharmaceutical Drug Development. Dr. Connelly received his B.S. in Biology from Syracuse University, his Ph.D. in Immunochemistry from the University of Rochester, and completed a postdoctoral fellowship in Molecular Parasitology at Michigan State University.
Wes Blakeslee
General Counsel
A former NASA engineer, Wes became a lawyer and after more than 20 years in private law practice joined the General Counsel's office at Johns Hopkins University where he practiced intellectual property and complex business law. In 2006, Wes was appointed Executive Director of Johns Hopkins Technology Transfer, transforming the office into one of the strongest in the US. He is Senator of the Industrial and Professional Advisory Council of the Penn State Department of Engineering Science and Mechanics, and in 2013 received the Penn State Outstanding Engineering Alumni Award the highest honor bestowed by the College of Engineering.
Anula Jayasuriya MD MBA PhD
Board Director
Anula founded EXXclaim Capital, an early-stage venture fund focused on catalyzing innovation, entrepreneurship and investment in Women’s Health, and co-founded EILSF, the first Indian fund focusing health care. She sits on several private biotech boards and on the boards of two public companies.
Previously, Anula was an investor at Skyline Ventures and TVM, VP Business Development at Genomics Collaborative Inc., and Vice President, Global Drug Development at Hoffman-La Roche.
Anula received her BA from Harvard summa cum laude, and an MD and PhD from Harvard Medical School. She interned in Pediatrics at Boston Children’s Hospital and earned an MBA with distinction from Harvard Business School.
Mark Myslinski
COO
Ryan Dittamore MBA
Chief Commercial Advisor
TERMS
StrandSmart
Overview
PRICE PER SHARE
$4.14
DEADLINE
Mar 21, 2023
VALUATION
$18.04M
FUNDING GOAL
$10k - $1.23M
Breakdown
MIN INVESTMENT
$496.80
MAX INVESTMENT
$1,234,995.12
MIN NUMBER OF SHARES OFFERED
2,415
MAX NUMBER OF SHARES OFFERED
298,308
OFFERING TYPE
Equity
SHARES OFFERED
Common Stock
Maximum Number of Shares Offered subject to adjustment for bonus shares
*Maximum number of shares offered subject to adjustment for bonus shares. See Bonus info below.
Voting Rights of Securities Sold in this Offering
Voting Proxy. Each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.
Investment Incentives and Bonuses*
Loyalty Bonus (Previous Investors):
StrandSmart would like to offer you 10% bonus shares
Time-Based:
Friends and Family
Invest within the first 48 hours and receive 15% bonus shares
Super Early Bird
Invest within the 72 hours and receive 10% bonus shares
Early Bird Bonus
Invest within the first week and receive 5% bonus shares
Amount-Based:
$5,000+
1st Tier
5% bonus shares
$10,000+
2nd Tier
10% bonus shares
$25,000+
3rd Tier
15% bonus shares
*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed.
The 10% StartEngine Owners' Bonus
SmartStrand, Inc. will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.
This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $4.14 / share, you will receive 110 shares of Common Stock, meaning you'll own 110 shares for $414. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.
This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.
Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and time of offering elapsed (if any). Eligible investors will also receive the Owner’s Bonus and the Prior Investor Loyalty Bonus in addition to the aforementioned bonus.
Irregular Use of Proceeds
The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments. Salary payments made to one’s self, a friend or relative.
ALL UPDATES
03.06.23
Our community joins in!
We're excited to see our community come in and invest in StrandSmart! Our Insiders have invested a total of $4,569.62 into the offering to date! We hope you join in as well!
Please refer to the Company’s offering materials for further information and refer to the Company’s Risk Factors.
Stack Owner's Bonus & Rewards!
Members get an extra 10% shares in addition to rewards below!
REWARDS
JOIN THE DISCUSSION
0/2500
David Schrift
4 months ago
Hi,
I had a few questions on revenue generation:
1. Can you elaborate on your timeline and pipeline for revenue generation with research/pharmaceutical firms? Do you have firms lined up? Expected range of revenue for each firm? Expected total yearly revenue? Margin expectations?
2. What are the barriers for long term revenue generation with commercialization and how do you plan on addressing them? (What is needed for FDA approval and timeline? How do you plan to get widespread adoption with oncologists? What type of studies do you expect to need to achieve these goals and how long and how expensive do you expect the studies to be?)
Thank you!
David
1
0
HOW INVESTING WORKS
Cancel anytime before 48 hours before a rolling close or the offering end date.
WHY STARTENGINE?
REWARDS
We want you to succeed and get the most out of your money by offering rewards and memberships!
SECURE
Your info is your info. We take pride in keeping it that way!
DIVERSE INVESTMENTS
Invest in over 200 start-ups and collectibles!
With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.
With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.
At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.
Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.
StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.
For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.
For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.
Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.
Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.
Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.
Janice Makela
4 months ago
1
0